Certain Wegovy Strengths Expected to Be in Short Supply
Wegovy is a glucagon-like peptide-1 receptor agonist.
Wegovy is a glucagon-like peptide-1 receptor agonist.
Researchers sought to reduce cardiometabolic risk in patients with obesity by placing them on a low calorie diet and a combination of exercise and liraglutide.
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress.
Previously, the treatment had been approved for patients 1 year of age and older.
The sNDA is supported by data from the phase 3, placebo-controlled APOLLO-B study.
CHAPLE disease is a rare genetic disorder caused by mutations in the CD55 gene.
Investigators from Texas Tech University searched publication databases for studies evaluating risk for diabetes mellitus, hypertension, dyslipidemia, and atherosclerotic macrovascular disease in the setting of ASD.
Velmanase alfa is a recombinant form of human lysosomal alpha-mannosidase intended to provide or supplement natural alpha-mannosidase.
The SURMOUNT-1 trial evaluated tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity or are overweight.